Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ET

Company Participants

Stephanie Diaz - Manager of Investor Relations

Brian Lian - President and CEO

Greg Zante - CFO

Conference Call Participants

Steven Seedhouse - Raymond James

Jay Olson - Oppenheimer

Joon Lee - Truist Securities

Andy Hsieh - William Blair

Yale Jen - Laidlaw & Co

Thomas Smith - Leerink Partners

Justin Zelin - BTIG

Dylan Dupuis - Roth MKM

Operator

Welcome to the Viking Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, July 26, 2023.

I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz

Hello and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO. Before we begin, I would like to caution that comments made during this conference call today, July 26, 2023, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, timelines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.

These forward-looking statements speak only as of today’s date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company’s filings with the Securities and Exchange Commission concerning these and other matters.

I will now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks, Stephanie, and good afternoon to everyone dialled in by phone or listening on the webcast. Today, we'll review our financial results for the second quarter and first six months of 2023, and provide an update on recent progress with our clinical programs and operations.

The first half of 2023 has been exceptional for Viking, with the company announcing positive clinical data from two programs and completing a successful financing to support the continued development of our pipeline. During the second quarter, we announced positive results from the Phase 2b VOYAGE Study of VK2809, in patients with biopsy confirmed nonalcoholic steatohepatitis or NASH. The study successfully achieved its primary endpoint, confirming VK2809's best-in-class therapeutic profile for the treatment of NASH.